An Outtier

408 total citations
22 papers, 178 citations indexed

About

An Outtier is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, An Outtier has authored 22 papers receiving a total of 178 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Genetics, 14 papers in Epidemiology and 8 papers in Surgery. Recurrent topics in An Outtier's work include Inflammatory Bowel Disease (17 papers), Microscopic Colitis (10 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). An Outtier is often cited by papers focused on Inflammatory Bowel Disease (17 papers), Microscopic Colitis (10 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). An Outtier collaborates with scholars based in Belgium, United Kingdom and United States. An Outtier's co-authors include Marc Ferrante, Séverine Vermeire, Bram Verstockt, Erwin Dreesen, Maja Noman, Gert Van Assche, Ann Gils, Isolde Aerden, Griet Compernolle and João Sabino and has published in prestigious journals such as Gastroenterology, Alimentary Pharmacology & Therapeutics and Clinical Gastroenterology and Hepatology.

In The Last Decade

An Outtier

19 papers receiving 177 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
An Outtier Belgium 6 149 102 60 54 17 22 178
Claire Liefferinckx Belgium 8 181 1.2× 136 1.3× 83 1.4× 55 1.0× 11 0.6× 23 230
Philippe Van Hootegem Belgium 6 131 0.9× 106 1.0× 59 1.0× 51 0.9× 14 0.8× 11 202
Chani Topf‐Olivestone Israel 6 218 1.5× 174 1.7× 81 1.4× 54 1.0× 36 2.1× 14 257
Anne-Laure Charlois France 7 122 0.8× 113 1.1× 38 0.6× 71 1.3× 17 1.0× 11 198
Fiorella Cañete Spain 8 116 0.8× 96 0.9× 47 0.8× 46 0.9× 11 0.6× 37 184
Vince Biemans Netherlands 8 315 2.1× 231 2.3× 104 1.7× 112 2.1× 32 1.9× 14 336
Laura Loy Italy 8 106 0.7× 68 0.7× 49 0.8× 41 0.8× 8 0.5× 22 166
P. Hindryckx Belgium 4 94 0.6× 96 0.9× 33 0.6× 43 0.8× 6 0.4× 4 152
Jana Sirotiaková Slovakia 6 86 0.6× 65 0.6× 53 0.9× 24 0.4× 27 1.6× 9 162
Vishal Patel United States 5 109 0.7× 101 1.0× 19 0.3× 31 0.6× 34 2.0× 11 158

Countries citing papers authored by An Outtier

Since Specialization
Citations

This map shows the geographic impact of An Outtier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by An Outtier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites An Outtier more than expected).

Fields of papers citing papers by An Outtier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by An Outtier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by An Outtier. The network helps show where An Outtier may publish in the future.

Co-authorship network of co-authors of An Outtier

This figure shows the co-authorship network connecting the top 25 collaborators of An Outtier. A scholar is included among the top collaborators of An Outtier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with An Outtier. An Outtier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Outtier, An, Rosanne Janssens, Liese Barbier, et al.. (2024). Evolution of Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials: A Clinical Trial Databank Analysis. United European Gastroenterology Journal. 13(4). 542–551. 2 indexed citations
3.
Siegel, Corey A., Victoria Rai, An Outtier, et al.. (2024). Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials. Journal of Crohn s and Colitis. 18(12). 1967–1975. 1 indexed citations
4.
Outtier, An, Édouard Louis, Olivier Dewit, et al.. (2024). Efficacy and Safety of Ustekinumab for Chronic Pouchitis: A Prospective Open-label Multicenter Study. Clinical Gastroenterology and Hepatology. 22(12). 2468–2474.e1. 5 indexed citations
5.
Outtier, An, E Louis, Olivier Dewit, et al.. (2023). P521 Effectiveness of ustekinumab as therapy for chronic antibiotic refractory pouchitis. Journal of Crohn s and Colitis. 17(Supplement_1). i649–i650.
6.
Outtier, An, Édouard Louis, Olivier Dewit, et al.. (2023). Tu1711 USTEKINUMAB AS INDUCTION AND MAINTENANCE THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS. Gastroenterology. 164(6). S–1089. 2 indexed citations
7.
Outtier, An, Sebastian G. Wicha, Alexander Kensert, et al.. (2022). Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases. CPT Pharmacometrics & Systems Pharmacology. 11(8). 1045–1059. 20 indexed citations
8.
Yskout, Koen, David Geerts, Pascal Borry, et al.. (2022). Using provocative design to foster electronic informed consent innovation. BMC Medical Informatics and Decision Making. 22(1). 296–296. 1 indexed citations
9.
Verstockt, Bram, Valery Volk, Dahham Alsoud, et al.. (2022). Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Alimentary Pharmacology & Therapeutics. 56(2). 282–291. 9 indexed citations
10.
Outtier, An, Édouard Louis, Olivier Dewit, et al.. (2022). Mo1570: EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS. Gastroenterology. 162(7). S–826. 3 indexed citations
11.
Outtier, An, et al.. (2022). Screening Failure in a Large Clinical Trial Centre for Inflammatory Bowel Diseases: Rates, Causes, and Outcomes. Inflammatory Bowel Diseases. 29(9). 1440–1445. 5 indexed citations
12.
13.
Outtier, An & Marc Ferrante. (2021). Chronic Antibiotic-Refractory Pouchitis: Management Challenges. Clinical and Experimental Gastroenterology. Volume 14. 277–290. 4 indexed citations
14.
Verstockt, Bram, Dahham Alsoud, An Outtier, et al.. (2021). Su462 ONE YEAR ENDOSCOPIC AND HISTOLOGIC OUTCOMES TO TOFACITINIB THERAPY IN REFRACTORY ULCERATIVE COLITIS. Gastroenterology. 160(6). S–702. 1 indexed citations
15.
Verstockt, Bram, An Outtier, João Sabino, et al.. (2020). Invasive nocardiosis, disseminated varicella zoster reactivation, and pneumocystis jiroveci pneumonia associated with tofacitinib and concomitant systemic corticosteroid use in ulcerative colitis. Journal of Gastroenterology and Hepatology. 35(12). 2294–2297. 4 indexed citations
16.
Verstockt, Bram, An Outtier, João Sabino, et al.. (2020). Mo1858 ENDOSCOPIC AND HISTOLOGIC OUTCOME IN TOFACITINIB TREATED REFRACTORY MODERATE-TO-SEVERE ULCERATIVE COLITIS: A PROSPECTIVE REAL-LIFE COHORT. Gastroenterology. 158(6). S–952. 1 indexed citations
17.
Colombel, Jean‐Frédéric, An Outtier, Marc Ferrante, et al.. (2020). P508 Safety and efficacy of combining biological therapies together or with small molecules in patients with inflammatory bowel disease: A retrospective multicentre national observational case series study. Journal of Crohn s and Colitis. 14(Supplement_1). S440–S442. 1 indexed citations
18.
Verstockt, Bram, An Outtier, João Sabino, et al.. (2020). P399 Endoscopic and histologic outcome in tofacitinib treated refractory moderate-to-severe ulcerative colitis: A prospective real-life cohort. Journal of Crohn s and Colitis. 14(Supplement_1). S369–S370. 3 indexed citations
19.
Verstockt, Bram, Erwin Dreesen, Maja Noman, et al.. (2019). Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates. Journal of Crohn s and Colitis. 13(7). 864–872. 80 indexed citations
20.
Verstockt, Bram, Evelien Mertens, Erwin Dreesen, et al.. (2019). Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. Journal of Crohn s and Colitis. 14(3). 332–341. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Claire Liefferinckx Breakdown of academic impact, for papers by Philippe Van Hootegem Breakdown of academic impact, for papers by Chani Topf‐Olivestone Breakdown of academic impact, for papers by Anne-Laure Charlois Breakdown of academic impact, for papers by Fiorella Cañete Breakdown of academic impact, for papers by Vince Biemans Breakdown of academic impact, for papers by Laura Loy Breakdown of academic impact, for papers by P. Hindryckx Breakdown of academic impact, for papers by Jana Sirotiaková Breakdown of academic impact, for papers by Vishal Patel
Rankless by CCL
2026